Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.70 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2490459 | 0.94 | PTGS2 (0.80) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL5112490 | 0.93 | PTGS2 (0.78) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL17378051 | 0.93 | PTGS2 (0.80) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL17378063 | 0.92 | PTGS2 (0.80) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL2490543 | 0.91 | PTGS2 (0.81) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL17378061 | 0.91 | PTGS2 (0.80) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL2489007 | 0.90 | PTGS2 (0.79) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL2489372 | 0.89 | PTGS2 (0.76) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL12106622 | 0.85 | PTGS2 (0.84) | PTGS2PTGS1HRH4 | |
| SCHEMBL5797033 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1HRH4HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160106712-A1 | FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2016-04-21 | — | — | US | disclosed |
| US-9216224-B2 | Fatty acid COX inhibitor derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20130065934-A1 | FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| WO-2011109681-A1 | FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160106712-A1 | FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES | PTGES, PTGES2, ALOX5 | PTGS2 7/4885PTGS1 4/4885HRH4 2792/4885 |
| US-20130065934-A1 | FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES | PTGES, ALOX5, PTGES2 | PTGS2 7/4885PTGS1 4/4885HRH4 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.